Document Detail

c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
MedLine Citation:
PMID:  23319435     Owner:  NLM     Status:  Publisher    
BACKGROUND: As patients with basal-like breast cancer (BLBC) have a poor prognosis and there is no specifically tailored therapy, molecular biological characterization of BLBC is necessary. c-Kit is a transmembrane receptor tyrosine kinase known to play important roles in various solid cancers. This study classified BLBCs from patients with breast carcinoma, and addressed the significance of c-Kit expression in these tumours. METHODS: Primary breast tumours were stained with antibodies against oestrogen receptor, progesterone receptor, human epidermal growth factor receptor (HER) 2, epidermal growth factor receptor (EGFR), cytokeratin 5/6 and c-Kit. The association between c-Kit, BLBC and survival was analysed. RESULTS: A total of 667 patients with breast cancer were followed up for a median of 39 (range 6-72) months. Some 190 tumours (28·5 per cent) were classified as triple-negative for breast cancer (negative for oestrogen receptor, progesterone receptor and HER2) and 149 (78·4 per cent) had characteristics of BLBC (positive for cytokeratin 5/6 and/or EGFR). c-Kit expression was detected in 111 (16·6 per cent) of 667 tumours. c-Kit-positive tumours were more commonly found among patients with BLBC (42 of 149, 28·2 per cent; P < 0·001) and in patients with nodal metastasis (47 of 216, 21·8 per cent; P = 0·014) than in those without. In patients with BLBC, the prognosis was significantly worse in those with c-Kit expression (P < 0·001). Multivariable logistic regression analysis revealed c-Kit as an independent negative prognostic factor for cancer-specific survival in patients with BLBC (hazard ratio 2·29, 95 per cent confidence interval 1·11 to 4·72). CONCLUSION: c-Kit might be a prognostic marker and possible molecular target for therapy in patients with BLBC. Copyright © 2012 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
S Kashiwagi; M Yashiro; T Takashima; N Aomatsu; H Kawajiri; Y Ogawa; N Onoda; T Ishikawa; K Wakasa; K Hirakawa
Related Documents :
23098285 - Simultaneous integrated boost in breast conserving radiotherapy: is replanning necessar...
25008065 - Positive immunohistochemical expression of bcl-2 in hormone-independent breast carcinom...
1314185 - Leptomeningeal carcinomatosis: a report of 3 cases and review of the literature.
24581525 - Fragmentation of transrectal ultrasound-guided biopsy cores is influenced by the method...
19351655 - Functional polymorphisms, altered gene expression and genetic association link nrh:quin...
17416755 - Gastric cancer is related to early helicobacter pylori infection in a high-prevalence c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-14
Journal Detail:
Title:  The British journal of surgery     Volume:  -     ISSN:  1365-2168     ISO Abbreviation:  Br J Surg     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372553     Medline TA:  Br J Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Next Document:  Interlaboratory studies and initiatives developing standards for proteomics.